ASTRAMORPH PF

Post-LOE

morphine sulfate

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Oct 1986

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ASTRAMORPH PF (morphine sulfate) by Fresenius Kabi is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Approved for severe, persistent pain, including immediate-release opioids. First approved in 1986.

Drug data last refreshed 18h ago

Mechanism of Action

mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…

Indications (3)

severe persistent pain

Worked on ASTRAMORPH PF at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT01595867Phase 1Completed

Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo

Started Aug 2010

33 enrolled

Narcotic AbuseOpioid-related DisordersAnalgesia+1 more

NCT00751478Phase 1/2Completed

Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)

Started Mar 2007

32 enrolled

Healthy